Citius reported growing LYMPHIR orders and $7.1 million of nine-month revenue, but losses, financing needs and safety risks remain important.

Key Points Citius Oncology, Inc. reports accelerating commercial momentum for LYMPHIR, its FDA‑approved treatment for cutaneous T‑cell lymphoma (CTCL).

Investing.com -- Shares of Citius Oncology Inc (NASDAQ:CTOR) soared by 33% following the announcement of a distribution services agreement with Cardinal Health (NYSE:CAH), a major player in pharmaceutical and specialty pharmaceutical distribution services in the United States. The partnership aims to facilitate the U.S. commercial launch of LYMPHIR™, an FDA-approved immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL). Citius Pharmaceuticals Inc (NASDAQ:CTXR), the parent company of Citius Oncology, also saw its shares climb by 6.7%. Meanwhile, Cardinal Health’s stock remained flat after the news. The distribution agreement is a strategic move for Citius Oncology as it prepares to introduce LYMPHIR™ to the market. Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals, expressed confidence in the partnership, stating, "This agreement marks a key step forward in our launch readiness efforts." He emphasized that Cardinal Health’s distribution expertise will ensure efficient and reliable access to LYMPHIR™ for healthcare providers and patients, as the company aims to establish a strong commercial distribution network. Cardinal Health is set to become an authorized distributor of record for Citius Oncology, providing specialty pharmaceutical distribution services that are expected to support the commercialization of LYMPHIR™. The announcement reflects a significant development for Citius Oncology and Citius Pharmaceuticals, as the distribution agreement with Cardinal Health is likely to enhance the availability and delivery of their new immunotherapy treatment to the market. Investors reacted positively to the news, as reflected in the uptick of Citius Oncology’s and Citius Pharmaceuticals’ stock prices. However, Cardinal Health’s stock did not register a significant change, indicating that the market may have already priced in the expected benefits of the agreement for the distribution giant or is awaiting further developments. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you invest $2,000 in CAH right now? With CAH making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed CAH alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including CAH, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is CAH poised for similar growth? Don't miss the opportunity to find out.